![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 22, 2013 10:51:13 PM
This has several ramifications. First the board make up will now be 4 representatives from DSS and 4 representatives from LTG. The ninth position will be filled by Richard Cohen.
Purchase Price Allocation if Lexington is determined to be the accounting acquirer:
In accordance with the accounting treatment of the Merger as a reverse acquisition, the fair value of the outstanding equity of the accounting acquiree immediately prior to the Merger is used to calculate the purchase price of the net assets by the combined company. The purchase price is allocated to the fair value of the acquired company’s assets and liabilities on the date of the Merger, with any remainder assigned to goodwill. The pro-forma unaudited balance sheet as of December 31, 2012 presented below reflects the allocation of the preliminary estimated purchase price of approximately $68 million which is the expected estimated fair value of DSS’s outstanding common stock on the date of the Merger based on share price of $3.12 which was the closing price of DSS common stock on May 3, 2013, and the outstanding stock of DSS as of May 3, 2013. The final purchase price allocation will depend significantly on DSS’s future share price and the final estimate of the fair value of the intangible assets acquired, and consequently, might significantly differ from the values presented in these pro-forma statements. While DSS uses its best estimates and assumptions as part of the purchase price allocation process to value, the assets acquired, the purchase price allocation is preliminary and could change during the measurement period (not to exceed one year) if new information is obtained about the facts and circumstances that existed as of the Merger date that, if known, would have resulted in the recognition of additional or changes to the value of the assets and liabilities presented in this proforma.
Purchase Price Allocation if DSS is determined to be the accounting acquirer:
In accordance with the accounting treatment of the Merger as a business combination in accordance with the Business Combination Topic of the FASB ASC 805. Under the guidance, the assets and liabilities of the acquired business, Lexington, are recorded at their fair values at the date of acquisition. The excess of the purchase price over the estimated fair values is recorded as goodwill, if any. If the fair value of the assets acquired exceeds the purchase price and the liabilities assumed then a gain on acquisition is recorded. The consideration transferred is measured based on the expected fair value of the DSS common stock, preferred stock and warrant issued by DSS to Lexington. The estimated fair value of the aggregate of 26,850,000 shares of DSS common stock and DSS preferred stock to be issued is $3.12 per share based on the closing price on May 3, 2013. For the purposes of this pro forma estimate, the fair value of the preferred shares is based on their immediate convertibility to DSS common stock. The fair value 4,859,894 warrants to be issued by DSS is estimated to be $6,103,231 using the Black-Scholes-Merton option pricing model. As a result, the total purchase price of approximately $90 million is allocated to the fair value of the assets of Lexington on the date of the Merger. The Company measured the identifiable assets acquired and liabilities assumed based on the acquisition date fair value. While DSS uses its best estimates and assumptions as part of the purchase price allocation process to value, the assets acquired, the purchase price allocation is preliminary and could change during the measurement period (not to exceed one year) if new information is obtained about the facts and circumstances that existed as of the Merger date that, if known, would have resulted in the recognition of additional or changes to the value of the assets and liabilities presented in this proforma.
What has to be considered is what does the price on the date of the "official filing" next week have on these values?
Recent DSS News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:15:31 PM
- Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." • GlobeNewswire Inc. • 01/30/2024 01:05:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:54:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:40 PM
- DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market • GlobeNewswire Inc. • 01/04/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:10:36 PM
- DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan • GlobeNewswire Inc. • 12/22/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:30:23 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/13/2023 09:15:25 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/01/2023 09:15:06 PM
- Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years • GlobeNewswire Inc. • 11/28/2023 01:10:00 PM
- DSS Inc. Wins Patent Dispute with Nichia Corporation • GlobeNewswire Inc. • 11/14/2023 01:00:00 PM
- DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock • GlobeNewswire Inc. • 11/08/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 09:25:10 PM
- DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule • GlobeNewswire Inc. • 10/26/2023 09:25:00 PM
- DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical • GlobeNewswire Inc. • 10/23/2023 12:25:00 PM
- DSS Inc. Issues Letter to Shareholders • GlobeNewswire Inc. • 10/12/2023 12:25:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:31:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:30:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/12/2023 08:30:20 PM
- DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary • GlobeNewswire Inc. • 09/06/2023 12:40:00 PM
- DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc. • GlobeNewswire Inc. • 07/31/2023 12:15:00 PM
- DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc. • GlobeNewswire Inc. • 07/05/2023 12:15:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM